Mar 14, 2023 / 05:20PM GMT
Matt Biegler - Oppenheimer & Co. Inc. - Analyst
Hey, good afternoon, everyone. Welcome to OpCo's Healthcare Conference.
Super pumped to be joined by our next speakers who are from IDEAYA, which is one of my favorite covered companies. We've got some of the brains of the operation here: Mike White, who's CSO; and Darrin, who's CMO. I'm excited to talk about some of the recent progress.
Questions and Answers:
Matt Biegler - Oppenheimer & Co. Inc. - AnalystWe've only got 30 minutes, though. So Mike, I guess I'll start with you. What kind of differentiates IDEAYA's synthetic lethality core tech or platform -- discovery platform from the rest? You apparently came from Pfizer, what attracted you to the company?
Mike White - IDEAYA Biosciences, Inc. - Chief Scientific Officer
Thanks. Thanks, Matt. So I'll be fast. I know you have a lot you want to get to. First, thanks so much for inviting us to your health conference here today.
As you know, IDEAYA is a precision medicine oncology company
Trustpilot
